Recombinant Jurkat T cells stably transfected to express both the firefly luciferase gene under the control of NFAT response elements, and human TIGIT (V-set and immunoglobulin domain-containing protein 9, VSIG9, V-set and transmembrane domain-containing protein 3, and VSTM3, GenBank Accession No. NM_173799).
Interested in screening and profiling inhibitors, blocking antibodies, or activators of TIGIT without the need to purchase and license the cell line? Check out our Cell Signaling Pathway Screening.
Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.
●
Synonyms
T-cell immunoreceptor with Ig and ITIM domains, V-set and immunoglobulin domain-containing protein 9, VSIG9, V-set and transmembrane domain-containing protein 3, VSTM3
●
Product Data Gallery
Anti-TIGIT neutralizing antibody induced the NFAT luciferase reporter activity in TIGIT/NFAT Reporter-Jurkat cells co-cultured with CD155/TCR Activator-CHO cells
Anti-TIGIT neutralizing antibody induced the NFAT luciferase reporter activity in TIGIT/NFAT Reporter-Jurkat cells, but not in control NFAT Reporter-Jurkat cells, when co-cultured with CD155/TCR Activator-CHO cells
Anti-TIGIT neutralizing antibody induced the NFAT luciferase reporter activity in TIGIT/NFAT Reporter-Jurkat cells when co-cultured with CD155/TCR Activator-CHO cells, but not with control TCR Activator-CHO cells
FACS analysis of cell surface expression of TIGIT in TIGIT/NFAT Reporter-Jurkat cells
The cell line has been screened using the PCR-based Venor®GeM Mycoplasma Detection kit (Sigma-Aldrich) to confirm the absence of Mycoplasma species.
Background
TIGIT is a co-inhibitory receptor that is highly expressed in Natural Killer (NK) cells, activated CD4+, CD8+ and regulatory T cells. Interaction with the poliovirus receptor (PVR; CD155) on antigen presenting cells, such as dendritic cells, recruits Src homology (SH) domain-containing protein tyrosine phosphatase SHP1 and SHP2 or the inositol phosphatase SHIP1 and SHIP2 to the TIGIT ITIM domain. This increases IL-10 release and suppresses NF-kB and NFAT T cell receptor (TCR) signaling, which blocks T cell proliferation and cytokine production. It serves as a competitive inhibitor of CD226, a co-stimulatory receptor for CD155. TIGIT targeting antibodies that block this T cell-intrinsic inhibitory effects have shown enhanced anti-tumor and anti-viral functions in preclinical studies.
References
1. Li M et.al. (2014) T-cell Immunoglobulin and ITIM Domain (TIGIT) Receptor/ Poliovirus Receptor (PVR) Ligand Engagement Suppresses Interferon-g Production of Natural Killer Cells via b-arrestin 2-mediated Negative Signaling. J Biol Chem. 289: 17647- 17657. 2. Stanietsky N. et.al. (2009) The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. PNAS. 106: 17858-17863. 3. Zhu et.al. (2016) Identification of CD112R as a novel checkpoint for human T cells. J Exp. Med. 213: 167-176. 4. Yu X. et.al. (2008) The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat.Immunol. 10: 48-57.
Storage/Stability
Store in liquid nitrogen immediately upon receipt.
Growth Media
For best results, it is highly recommended to use these validated and optimized media from BPS Bioscience. Other preparations or formulations of media may result in suboptimal performance.
Growth Medium 2A (BPS Cat. #60190): RPMI1640 medium supplemented with 10% FBS, 1% Penicillin/Streptomycin plus 1 mg/ml of Geneticin and 200 μg/ml of Hygromycin B
Instructions for Use
See product datasheet for detailed protocol.
Applications
• Screen for compound activity of TIGIT signaling in a cellular context. • Characterize the biological activity of TIGIT and its interactions with ligands
Shipping Temperature
dry ice
Notes
License Disclosure Visit bpsbioscience.com/license for the label license and other key information about this product.